| Mark A Posner, MD | |
|
470 Sentry Pkwy E, Ste 200, Blue Bell, PA 19422-2324 | |
| (610) 825-5800 | |
| (610) 397-0980 |
| Full Name | Mark A Posner |
|---|---|
| Gender | Male |
| Speciality | Allergy/immunology |
| Experience | 39 Years |
| Location | 470 Sentry Pkwy E, Blue Bell, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508869637 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207K00000X | Allergy & Immunology | MD041379L (Pennsylvania) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Psf Pllc | 1557265543 | 98 |
News Archive
Like childhood cancers, early life epilepsies represent many rare disorders with diverse underlying causes. Unlike childhood cancers, little has changed in the outcomes of early life epilepsies in the past few decades, despite advances in diagnostic technologies and availability of new treatments.
X-spine, a global leader in the design and manufacture of devices for the treatment of spinal disease, announces the market launch of three recently USFDA-cleared spinal implant systems. The systems are the IRIX-C cervical integrated interbody fusion system, the AXLE-X extended angle interspinous fixation system and the SILEX™ sacroiliac joint fusion system .
The research just published by a group of scientists from the Centre for Genomic Regulation (CRG) in Barcelona, Spain, led by Eulàlia Martí, in cooperation with researchers from the University of Barcelona (UB) and August Pi i Sunyer Biomedical Research Institute (IDIBAPS), has brought to light new information on the molecular mechanisms that cause Huntington's disease, and defines new pathways to therapy discovery.
Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.
› Verified 1 days ago
| Entity Name | Allergy & Asthma Specialists Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144290016 PECOS PAC ID: 2466422670 Enrollment ID: O20040727000474 |
News Archive
Like childhood cancers, early life epilepsies represent many rare disorders with diverse underlying causes. Unlike childhood cancers, little has changed in the outcomes of early life epilepsies in the past few decades, despite advances in diagnostic technologies and availability of new treatments.
X-spine, a global leader in the design and manufacture of devices for the treatment of spinal disease, announces the market launch of three recently USFDA-cleared spinal implant systems. The systems are the IRIX-C cervical integrated interbody fusion system, the AXLE-X extended angle interspinous fixation system and the SILEX™ sacroiliac joint fusion system .
The research just published by a group of scientists from the Centre for Genomic Regulation (CRG) in Barcelona, Spain, led by Eulàlia Martí, in cooperation with researchers from the University of Barcelona (UB) and August Pi i Sunyer Biomedical Research Institute (IDIBAPS), has brought to light new information on the molecular mechanisms that cause Huntington's disease, and defines new pathways to therapy discovery.
Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.
› Verified 1 days ago
| Entity Name | Psf Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881785947 PECOS PAC ID: 1557265543 Enrollment ID: O20210807000032 |
News Archive
Like childhood cancers, early life epilepsies represent many rare disorders with diverse underlying causes. Unlike childhood cancers, little has changed in the outcomes of early life epilepsies in the past few decades, despite advances in diagnostic technologies and availability of new treatments.
X-spine, a global leader in the design and manufacture of devices for the treatment of spinal disease, announces the market launch of three recently USFDA-cleared spinal implant systems. The systems are the IRIX-C cervical integrated interbody fusion system, the AXLE-X extended angle interspinous fixation system and the SILEX™ sacroiliac joint fusion system .
The research just published by a group of scientists from the Centre for Genomic Regulation (CRG) in Barcelona, Spain, led by Eulàlia Martí, in cooperation with researchers from the University of Barcelona (UB) and August Pi i Sunyer Biomedical Research Institute (IDIBAPS), has brought to light new information on the molecular mechanisms that cause Huntington's disease, and defines new pathways to therapy discovery.
Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mark A Posner, MD 9800 Shelbyville Rd, Ste 220, Louisville, KY 40223-2992 Ph: (502) 429-8585 | Mark A Posner, MD 470 Sentry Pkwy E, Ste 200, Blue Bell, PA 19422-2324 Ph: (610) 825-5800 |
News Archive
Like childhood cancers, early life epilepsies represent many rare disorders with diverse underlying causes. Unlike childhood cancers, little has changed in the outcomes of early life epilepsies in the past few decades, despite advances in diagnostic technologies and availability of new treatments.
X-spine, a global leader in the design and manufacture of devices for the treatment of spinal disease, announces the market launch of three recently USFDA-cleared spinal implant systems. The systems are the IRIX-C cervical integrated interbody fusion system, the AXLE-X extended angle interspinous fixation system and the SILEX™ sacroiliac joint fusion system .
The research just published by a group of scientists from the Centre for Genomic Regulation (CRG) in Barcelona, Spain, led by Eulàlia Martí, in cooperation with researchers from the University of Barcelona (UB) and August Pi i Sunyer Biomedical Research Institute (IDIBAPS), has brought to light new information on the molecular mechanisms that cause Huntington's disease, and defines new pathways to therapy discovery.
Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.
› Verified 1 days ago
Matthew I Fogg, MD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 470 Sentry Pkwy E, Ste 200, Blue Bell, PA 19422 Phone: 610-825-5800 Fax: 610-397-0980 | |
Dr. Patrick Michael Vannelli, MD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 470 Sentry Pkwy E, Suite 200, Blue Bell, PA 19422 Phone: 610-825-5800 Fax: 610-397-0980 | |
Mark S Lepore, MD Allergy & Immunology Medicare: Not Enrolled in Medicare Practice Location: 470 Sentry Pkwy E, Ste 200, Blue Bell, PA 19422 Phone: 610-825-5800 Fax: 610-397-0980 | |
Niti Agarwal, Allergy & Immunology Medicare: Medicare Enrolled Practice Location: 470 Sentry Pkwy E Ste 200, Blue Bell, PA 19422 Phone: 610-825-5800 Fax: 610-397-0980 | |
Nora J Lin, MD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 470 Sentry Pkwy E, Ste 200, Blue Bell, PA 19422 Phone: 610-825-5800 Fax: 610-397-0980 | |
Robert Anolik, MD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 470 Sentry Pkwy E, Ste 200, Blue Bell, PA 19422 Phone: 610-825-5800 Fax: 610-397-0980 | |
Dr. David Stuart Krause, MD Allergy & Immunology Medicare: Medicare Enrolled Practice Location: 147 Sawgrass Drive, Blue Bell, PA 19422 Phone: 215-280-9425 |